Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

Raytheon Technologies Corp (RTX) on Tuesday revised down its full-year revenue forecast, citing the loss of sales to Russia after Western sanctions.

The aerospace and defense company now forecasts its 2022 revenue to fall within the range of $67.75 billion and $68.75 billion, compared with a prior forecast of $68.5 billion to $69.5 billion.

According to Raytheon’s Chief Financial Officer Neil Mitchill, the downward revision of the 2022 guidance by $750 million “was strictly related to direct and indirect sales that are no longer allowed because of the global sanctions imposed on Russia.”

Raytheon’s total revenue surged 3% year-on-year to $15.72 billion during the latest quarter, underpinned by air travel demand recovery.

Sales at the company’s Missiles & Defense business shrank 7% compared to the same period a year earlier, while sales at Raytheon Intelligence & Space dropped 5% year-on-year, after the company sold its Global Training and Services business to Vertex Aerospace.

Raytheon reported a net income of $1.08 billion ($0.72 per share) during the quarter ended on March 31st, compared with income of $753 million ($0.50 per share) in the year-ago quarter.

Excluding special items, the firm earned $1.15 per share during the latest quarter, which compares with a market consensus of $1.02 per share.

Raytheon shares closed lower for a fourth consecutive trading session in New York on Tuesday. The stock went down 0.42% ($0.42) to $99.19, after touching an intraday low at $96.78. The latter has been a price level not seen since March 18th ($96.33).

The shares of Raytheon Technologies Corp have risen 15.26% so far in 2022 compared with a 12.40% loss for the benchmark index, S&P 500 (SPX).

Analyst stock price forecast and recommendation

According to TipRanks, all 7 surveyed investment analysts had rated Raytheon Technologies Corp’s stock as “Buy”. The median price target on the stock stands at $118.57.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • Forex Market: USD/CAD daily trading outlookForex Market: USD/CAD daily trading outlook Fridays trade saw USD/CAD within the range of 1.2398 - 1.2309. The pair closed 0.1% lower at 1.2318, settling the week 0.4% higher and ending three straight weekly declines.At 07:40 GMT today USD/CAD was down 0.01% for the day to trade at […]
  • Forex Market: CHF/JPY daily forecastForex Market: CHF/JPY daily forecast During Friday’s trading session CHF/JPY traded within the range of 112.48-112.94 and closed at 112.55, losing 0.19% for the day.At 8:44 GMT today CHF/JPY was gaining 0.09% for the day to trade at 112.65. The pair touched a daily high at […]
  • Apple to battle lower cost tablets with new iPadApple to battle lower cost tablets with new iPad Apple Inc. is adding a new model to its iPad series to battle a growing list of competitors, which manage to present their own tablets at lower prices with similar features. Chief Executive Officer Tim Cook will debut a high-definition iPad […]
  • Silver Drops from Record High, Keeps Bull TrendSilver Drops from Record High, Keeps Bull Trend Key Moments Silver (XAG/USD) reached a new all-time high of $94.76 and later traded near $94.20 during European hours on Tuesday. The 14-day RSI at 72.81 indicates overbought conditions and raises the risk of short-term […]
  • USD/CHF hit session highsUSD/CHF hit session highs US dollar advanced to its highest point against the Swiss franc on Tuesday, after the release of optimistic economic data out of China, which supported outlook over world’s second largest economy and safe haven demand for currencies such as […]
  • Eli Lilly shares close lower on Wednesday, quarterly results mixed, full-year adjusted profit forecast revised upEli Lilly shares close lower on Wednesday, quarterly results mixed, full-year adjusted profit forecast revised up Eli Lilly and Company’s quarterly profit, reported on Wednesday, topped Wall Street estimates, supported by sales of its Humalog diabetes drug and by lower tax bill.Eli Lilly shares closed lower for the fifth time in the past eleven […]